Notable Analyst Calls This Week: Disney, Super Micro and Amgen Among Top Picks
12 Out of 17 Healthcare Companies Beat Profit Estimates This Week- Earnings Scorecard
Gilead Exits J&J Royalty Deal for Liver Drug Ahead of Potential FDA Nod
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $72
Adaptimmune Q2 2024 Earnings Preview
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels